[1] Zheng, L.H. and Liu, R. (2015) Contralateral Breast Cancer Risk Factors. Chinese Journal of Cancer, 37, 241-243.
[2] Jiang, Z.F. (2015) Effect of Molecular Classification of Breast Cancer on Treatment. Chinese Journal of General Surgery (Electronic Version), 9, 12-15.
[3] Zhang, H., Wang, W., Tian, T., et al. (2016) Expression and Significance of Ezrin in Triple Negative Breast Cancer. Journal of Xi'an Jiaotong University: Medical Science, 37, 574-577.
[4] Goldhirsch, A., Winer, E.P., Coates, A.S., et al. (2013) Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 24, 2206-2223.
https://doi.org/10.1093/annonc/mdt303
[5] Yuan, Y.W. (2015) The Latest Treatment and Research Progress of Triple Negative Breast Cancer. Chongqing Medical, 44, 2279-2282.
[6] Tan, Q.Z. and Liu, D. (2014) Analysis of Clinicopathological Features and Prognostic Factors of Triple-Negative Breast Cancer and non-Tri-Negative Breast Cancer. Practical Journal of Cancer, 29, 1480-1482.
[7] Yang, M., Dai, D.L., Cui, G.Z., Chen, L. and Ding, M.J. (2015) Clinical Pathological Classification and Pathological Features of Triple-Negative Breast Cancer and Non-Triple Negative. Modern Journal of Integrated Traditional Chinese and Western Medicine, 24, 2713-2715.
[8] Shen, S.D., Chen, Z.R., Huang, Z., Xiao, G.F. and Lei, R.W. (2012) Expression and Significance of Ki67 in Different Molecular Types of Breast Cancer. The Practical Journal of Cancer, 27, 247-249.
[9] Han, J.G., Jiang, Y.D., Zhang, G.H., et al. (2011) Clinicopathologic Characteristics and Prognosis of Young Patients with Breast Cancer. Breast, 20, 370-372.
https://doi.org/10.1016/j.breast.2011.02.011
[10] Weigel, M.T. and Dowsett, M. (2010) Current and Emerging Biomarkers in Breast Cancer: Prognosis and Prediction. Endocrine-Related Cancer, 17, 245-262.
https://doi.org/10.1677/ERC-10-0136
[11] Chen, N., Wang, H., et al. (2014) Expression of CK5/6 in Triple-Negative Breast Cancer. Journal of Modern Oncology, 22, 1334-1336.
[12] Bertucct, F., Fineth, P., Cervera, N., et al. (2008) How Basal Are Triple-Negative Breast Cancers? International Journal of Cancer, 123, 236-240.
https://doi.org/10.1002/ijc.23518
[13] Choi, J., Jung, W.H. and Koo, J.S. (2012) C1inicopathologic Features of Molecular Subtypes of Triple Negative Breast Cancer Based on Immunohistochemical Markers. Histology and Histopathology, 27, 1481.
[14] Prak, H.S., Jang, M.H., Kim, E.J., et al. (2014) High EGFR Gene Copy Number Predicts Poor Outcome in Triple-Negative Breast Cancer. Modern Pathology, 27, 1212-1222.
https://doi.org/10.1038/modpathol.2013.251
[15] Baselga, J., Gomez, P., Greil, R., et al. (2013) Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab with Cisplatin versus Cisplatin Alone in Patients with Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 31, 2586-2592.
https://doi.org/10.1200/JCO.2012.46.2408
[16] Liu, T., Shen, M., Wang, D., et al. (2014) Effects of Expression of MMP-9 and E-Cadherin in Triple-Negative Breast Cancer. Journal of Practical Oncology, 28, 19-23.
[17] Yin, T., Chen, X., Yu, H., et al. (2009) Effects of VPA and SAHA on Apoptosis of Endometrial Carcinoma Cells and E-Cad Gene Expression. Chinese Journal of Clinical Oncology, 36, 1120-1124.